AC Immune (NASDAQ:ACIU) Trading 5% Higher – What’s Next?

AC Immune (NASDAQ:ACIU) traded up 5% during trading on Monday . The stock traded as high as $3.20 and last traded at $3.18. 290,098 shares changed hands during trading, a decline of 80% from the average session volume of 1,442,496 shares. The stock had previously closed at $3.03.

Wall Street Analysts Forecast Growth

Several research firms recently commented on ACIU. Weiss Ratings restated a “sell (d-)” rating on shares of AC Immune in a research note on Wednesday, October 8th. BTIG Research reissued a “buy” rating and set a $8.00 target price on shares of AC Immune in a research note on Tuesday, November 4th. Finally, Zacks Research upgraded AC Immune from a “strong sell” rating to a “hold” rating in a research note on Tuesday, September 9th. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $10.00.

AC Immune Trading Up 5.0%

The firm has a market capitalization of $319.30 million, a PE ratio of -3.79 and a beta of 1.60. The business has a 50-day moving average of $3.09 and a 200 day moving average of $2.60.

AC Immune (NASDAQ:ACIU) last released its earnings results on Tuesday, November 4th. The company reported ($0.20) EPS for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.02. AC Immune had a negative return on equity of 84.32% and a negative net margin of 1,642.89%.The company had revenue of $1.18 million for the quarter, compared to analysts’ expectations of $0.81 million. On average, sell-side analysts expect that AC Immune will post -0.62 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. BVF Inc. IL increased its stake in AC Immune by 1.5% in the 1st quarter. BVF Inc. IL now owns 19,822,436 shares of the company’s stock worth $37,068,000 after purchasing an additional 300,000 shares during the period. Acadian Asset Management LLC raised its stake in AC Immune by 87.1% in the first quarter. Acadian Asset Management LLC now owns 371,177 shares of the company’s stock worth $679,000 after buying an additional 172,796 shares in the last quarter. Sei Investments Co. bought a new stake in shares of AC Immune during the second quarter valued at approximately $51,000. Assenagon Asset Management S.A. bought a new stake in shares of AC Immune during the 3rd quarter valued at $549,000. Finally, Private Advisor Group LLC bought a new position in shares of AC Immune during the third quarter valued at approximately $48,000. Institutional investors own 51.36% of the company’s stock.

About AC Immune

AC Immune AG is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, with a subsidiary in Boston, Massachusetts. The company specializes in the discovery and development of therapeutics and diagnostics for neurodegenerative diseases, with a primary focus on Alzheimer’s disease, Parkinson’s disease and other protein misfolding disorders. AC Immune leverages proprietary platform technologies to identify and optimize candidates that target pathological protein aggregates.

Since its founding in 2003, AC Immune has advanced multiple programs into clinical development.